San Francisco, 7
September 2018: The global next
generation cancer diagnostics market is anticipated to reach USD 11.04 billion by 2024,
according to a new report by Grand View Research, Inc. Key drivers for this
vertical include rising advancement in genomics and proteomics-based research
coupled with increasing prevalence of oncology disorders.
Rise in
number of oncological research projects to elucidate tumorigenesis and the
underlying mechanisms, consequently raising the demand for serial sampling,
diagnosis, and therapeutic manipulation, is a growth rendering driver of this
market.
Access Research Report
of Next Generation Cancer
Diagnostics Market@: www.grandviewresearch.com/industry-analysis/next-generation-cancer-diagnostics-market
Further Key Findings from the Study Suggest:
· The qPCR & multiplexing segment
captured the largest market share in 2015 owing to the presence of a wide
product portfolio serving numerous applications in oncology R&D
· Next generation sequencing services and
solutions for oncology applications are anticipated to be the fastest growing
segment
· Oncology diagnostics in biomarker discovery
is expected witness growth as it subsequently facilitates drug designing and
identification of novel targets against tumors
· On the basis of cancer type, this vertical
is segmented into lung, breast, colorectal, cervical, and other forms of cancer
· Research projects to establish the
therapeutic index of anticancer cytotoxic drugs are one of the key factors
responsible for expected growth
· North America dominated the market with
respect to revenue generation in 2014 due to concerted efforts directed toward
the development of next generation sequencing technology and companion
diagnostics in personalized medicine
· Some of the key players contributing
significantly to the next generation cancer diagnostics market are Novartis AG;
Cepheid; Hoffman La Roche Ltd.; PerkinElmer, Inc.; Sysmex Corporation; Abbott;
Thermo Fisher Scientific, Inc.; Koninklijke Philips N.V.; Agilent Technologies;
Illumina, Inc.; Genomic Health, Inc.; Qiagen; Janssen Global Services, LLC;
Hologic, Inc.; Myriad Genetics, Inc.; Almac Group; Opko Health, Inc.; and GE
Healthcare.
Browse more reports of
this category by Grand View Research at: www.grandviewresearch.com/industry/biotechnology
Grand View
Research has segmented the next generation cancer diagnostics market on the
basis of technology, application, cancer type, function, and region:
Technology
Outlook (Revenue, USD Million, 2013 - 2024)
·
Next Generation Sequencing
·
qPCR & Multiplexing
·
Lab-on- a- chip (LOAC) & Reverse
Transcriptase-PCR (RT-PCR)
·
Protein Microarrays
·
DNA Microarrays
Application
Outlook (Revenue, USD Million, 2013 - 2024)
·
Biomarker Development
·
CTC Analysis
·
Proteomic Analysis
·
Epigenetic Analysis
·
Genetic Analysis
Cancer Type
Outlook (Revenue, USD Million, 2013 - 2024)
·
Lung Cancer
·
Breast Cancer
·
Colorectal Cancer
·
Cervical Cancer
·
Others
Function
Outlook (Revenue, USD Million, 2013 - 2024)
·
Therapeutic Monitoring
·
Companion Diagnostics
·
Prognostics
·
Cancer Screening
·
Risk Analysis
Regional
Outlook (Revenue, USD Million, 2013 - 2024)
·
North America
o
U.S
o
Canada
·
Europe
o
Germany
o
France
·
Asia Pacific
o
Japan
o
China
·
Latin America
o
Brazil
·
Middle East & Africa
o
South Africa
Access Press Release of
Next Generation Cancer Diagnostics Market@: www.grandviewresearch.com/press-release/global-next-generation-cancer-diagnostics-market
About
Grand View Research
Grand
View Research, Inc. is a U.S. based market research and consulting company,
registered in the State of California and headquartered in San Francisco.
The company provides syndicated research reports, customized research reports, and consulting services. To help
clients make informed business decisions, we offer market intelligence studies ensuring relevant and
fact-based research across a range of industries, from technology to chemicals,
materials and healthcare.
For More Information: www.grandviewresearch.com
No comments:
Post a Comment